Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Optimization of a calcium-dependent Protein A-derived domain for mild antibody purification.

Scheffel J, Kanje S, Borin J, Hober S.

MAbs. 2019 Nov-Dec;11(8):1492-1501. doi: 10.1080/19420862.2019.1662690. Epub 2019 Sep 17.

2.

Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.

Liu H, Lindbo S, Ding H, Altai M, Garousi J, Orlova A, Tolmachev V, Hober S, Gräslund T.

Int J Oncol. 2019 Jul;55(1):309-319. doi: 10.3892/ijo.2019.4814. Epub 2019 May 28.

PMID:
31180549
3.

Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.

von Witting E, Garousi J, Lindbo S, Vorobyeva A, Altai M, Oroujeni M, Mitran B, Orlova A, Hober S, Tolmachev V.

Eur J Pharm Biopharm. 2019 Jul;140:109-120. doi: 10.1016/j.ejpb.2019.05.008. Epub 2019 May 10.

4.

Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.

Garousi J, Lindbo S, Borin J, von Witting E, Vorobyeva A, Oroujeni M, Mitran B, Orlova A, Buijs J, Tolmachev V, Hober S.

Eur J Pharm Biopharm. 2019 Jan;134:37-48. doi: 10.1016/j.ejpb.2018.11.004. Epub 2018 Nov 5.

5.

Enhanced validation of antibodies for research applications.

Edfors F, Hober A, Linderbäck K, Maddalo G, Azimi A, Sivertsson Å, Tegel H, Hober S, Szigyarto CA, Fagerberg L, von Feilitzen K, Oksvold P, Lindskog C, Forsström B, Uhlen M.

Nat Commun. 2018 Oct 8;9(1):4130. doi: 10.1038/s41467-018-06642-y.

6.

Bispecific applications of non-immunoglobulin scaffold binders.

Hober S, Lindbo S, Nilvebrant J.

Methods. 2019 Feb 1;154:143-152. doi: 10.1016/j.ymeth.2018.09.010. Epub 2018 Oct 1. Review.

7.

Quantum Dot-Based FRET Immunoassay for HER2 Using Ultrasmall Affinity Proteins.

Wu YT, Qiu X, Lindbo S, Susumu K, Medintz IL, Hober S, Hildebrandt N.

Small. 2018 Aug;14(35):e1802266. doi: 10.1002/smll.201802266. Epub 2018 Aug 5.

PMID:
30079524
8.

Protein Engineering Allows for Mild Affinity-based Elution of Therapeutic Antibodies.

Kanje S, Venskutonytė R, Scheffel J, Nilvebrant J, Lindkvist-Petersson K, Hober S.

J Mol Biol. 2018 Sep 14;430(18 Pt B):3427-3438. doi: 10.1016/j.jmb.2018.06.004. Epub 2018 Jun 7.

9.

Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga.

Lindbo S, Garousi J, Mitran B, Vorobyeva A, Oroujeni M, Orlova A, Hober S, Tolmachev V.

Mol Pharm. 2018 Jul 2;15(7):2674-2683. doi: 10.1021/acs.molpharmaceut.8b00204. Epub 2018 Jun 20.

PMID:
29865791
10.

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.

Garousi J, Lindbo S, Mitran B, Buijs J, Vorobyeva A, Orlova A, Tolmachev V, Hober S.

Sci Rep. 2017 Nov 7;7(1):14780. doi: 10.1038/s41598-017-15366-w.

11.

Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.

Lindbo S, Garousi J, Mitran B, Altai M, Buijs J, Orlova A, Hober S, Tolmachev V.

J Nucl Med. 2018 Jan;59(1):93-99. doi: 10.2967/jnumed.117.197202. Epub 2017 Sep 1.

12.

A pathology atlas of the human cancer transcriptome.

Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F.

Science. 2017 Aug 18;357(6352). pii: eaan2507. doi: 10.1126/science.aan2507.

PMID:
28818916
13.

A subcellular map of the human proteome.

Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, Bäckström A, Danielsson F, Fagerberg L, Fall J, Gatto L, Gnann C, Hober S, Hjelmare M, Johansson F, Lee S, Lindskog C, Mulder J, Mulvey CM, Nilsson P, Oksvold P, Rockberg J, Schutten R, Schwenk JM, Sivertsson Å, Sjöstedt E, Skogs M, Stadler C, Sullivan DP, Tegel H, Winsnes C, Zhang C, Zwahlen M, Mardinoglu A, Pontén F, von Feilitzen K, Lilley KS, Uhlén M, Lundberg E.

Science. 2017 May 26;356(6340). pii: eaal3321. doi: 10.1126/science.aal3321. Epub 2017 May 11.

PMID:
28495876
14.

Next generation of labeling reagents for quantitative and multiplexing immunoassays by the use of LA-ICP-MS.

Kanje S, Herrmann AJ, Hober S, Mueller L.

Analyst. 2016 Nov 14;141(23):6374-6380.

PMID:
27805202
15.

Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.

Garousi J, Lindbo S, Honarvar H, Velletta J, Mitran B, Altai M, Orlova A, Tolmachev V, Hober S.

Bioconjug Chem. 2016 Nov 16;27(11):2678-2688. Epub 2016 Oct 27.

PMID:
27740752
16.

Site-Specific Photolabeling of the IgG Fab Fragment Using a Small Protein G Derived Domain.

Kanje S, von Witting E, Chiang SC, Bryceson YT, Hober S.

Bioconjug Chem. 2016 Sep 21;27(9):2095-102. doi: 10.1021/acs.bioconjchem.6b00346. Epub 2016 Aug 15.

PMID:
27491005
17.

Investigating affinity-maturation strategies and reproducibility of fluorescence-activated cell sorting using a recombinant ADAPT library displayed on staphylococci.

Åstrand M, Nilvebrant J, Björnmalm M, Lindbo S, Hober S, Löfblom J.

Protein Eng Des Sel. 2016 May;29(5):187-95. doi: 10.1093/protein/gzw006. Epub 2016 Mar 15.

PMID:
26984961
18.

Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins.

Lindbo S, Garousi J, Åstrand M, Honarvar H, Orlova A, Hober S, Tolmachev V.

Bioconjug Chem. 2016 Mar 16;27(3):716-26. doi: 10.1021/acs.bioconjchem.5b00677. Epub 2016 Jan 29.

PMID:
26781756
19.

Antibodies as means for selective mass spectrometry.

Boström T, Takanen JO, Hober S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 15;1021:3-13. doi: 10.1016/j.jchromb.2015.10.042. Epub 2015 Oct 31. Review.

PMID:
26565067
20.

ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.

Garousi J, Lindbo S, Nilvebrant J, Åstrand M, Buijs J, Sandström M, Honarvar H, Orlova A, Tolmachev V, Hober S.

Cancer Res. 2015 Oct 15;75(20):4364-71. doi: 10.1158/0008-5472.CAN-14-3497. Epub 2015 Aug 21.

21.

Erratum to: Association of chromosome 19 to lung cancer genotypes and phenotypes.

Wang X, Zhang Y, Nilsson CL, Berven FS, Andrén PE, Carlsohn E, Horvatovich P, Malm J, Fuentes M, Végvári Á, Welinder C, Fehniger TE, Rezeli M, Edula G, Hober S, Nishimura T, Marko-Varga G.

Cancer Metastasis Rev. 2015 Jun;34(2):227. doi: 10.1007/s10555-015-9571-3.

PMID:
26143031
22.

Association of chromosome 19 to lung cancer genotypes and phenotypes.

Wang X, Zhang Y, Nilsson CL, Berven FS, Andrén PE, Carlsohn E, Horvatovich P, Malm J, Fuentes M, Végvári Á, Welinder C, Fehniger TE, Rezeli M, Edula G, Hober S, Nishimura T, Marko-Varga G.

Cancer Metastasis Rev. 2015 Jun;34(2):217-26. doi: 10.1007/s10555-015-9556-2. Review. Erratum in: Cancer Metastasis Rev. 2015 Jun;34(2):227.

PMID:
25982285
23.
24.

Proteomics. Tissue-based map of the human proteome.

Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F.

Science. 2015 Jan 23;347(6220):1260419. doi: 10.1126/science.1260419.

25.

Use of ENCODE resources to characterize novel proteoforms and missing proteins in the human proteome.

Nilsson CL, Mostovenko E, Lichti CF, Ruggles K, Fenyö D, Rosenbloom KR, Hancock WS, Paik YK, Omenn GS, LaBaer J, Kroes RA, Uhlén M, Hober S, Végvári Á, Andrén PE, Sulman EP, Lang FF, Fuentes M, Carlsohn E, Emmett MR, Moskal JR, Berven FS, Fehniger TE, Marko-Varga G.

J Proteome Res. 2015 Feb 6;14(2):603-8. doi: 10.1021/pr500564q. Epub 2014 Nov 26.

PMID:
25369122
26.

Investigating the applicability of antibodies generated within the human protein atlas as capture agents in immunoenrichment coupled to mass spectrometry.

Boström T, Johansson HJ, Lehtiö J, Uhlén M, Hober S.

J Proteome Res. 2014 Oct 3;13(10):4424-35. doi: 10.1021/pr500691a. Epub 2014 Sep 25.

PMID:
25231543
27.

Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin.

Nilvebrant J, Åstrand M, Georgieva-Kotseva M, Björnmalm M, Löfblom J, Hober S.

PLoS One. 2014 Aug 4;9(8):e103094. doi: 10.1371/journal.pone.0103094. eCollection 2014.

28.

Immunoproteomics using polyclonal antibodies and stable isotope-labeled affinity-purified recombinant proteins.

Edfors F, Boström T, Forsström B, Zeiler M, Johansson H, Lundberg E, Hober S, Lehtiö J, Mann M, Uhlen M.

Mol Cell Proteomics. 2014 Jun;13(6):1611-24. doi: 10.1074/mcp.M113.034140. Epub 2014 Apr 10.

29.

An orthogonal fusion tag for efficient protein purification.

Nilvebrant J, Astrand M, Hober S.

Methods Mol Biol. 2014;1129:205-10. doi: 10.1007/978-1-62703-977-2_18.

PMID:
24648079
30.

Zbasic: a purification tag for selective ion-exchange recovery.

Hedhammar M, Nilvebrant J, Hober S.

Methods Mol Biol. 2014;1129:197-204. doi: 10.1007/978-1-62703-977-2_17.

PMID:
24648078
31.

Antibody performance in western blot applications is context-dependent.

Algenäs C, Agaton C, Fagerberg L, Asplund A, Björling L, Björling E, Kampf C, Lundberg E, Nilsson P, Persson A, Wester K, Pontén F, Wernérus H, Uhlén M, Ottosson Takanen J, Hober S.

Biotechnol J. 2014 Mar;9(3):435-45. doi: 10.1002/biot.201300341. Epub 2014 Jan 29.

PMID:
24403002
32.

Integrated chromosome 19 transcriptomic and proteomic data sets derived from glioma cancer stem-cell lines.

Lichti CF, Liu H, Shavkunov AS, Mostovenko E, Sulman EP, Ezhilarasan R, Wang Q, Kroes RA, Moskal JC, Fenyö D, Oksuz BA, Conrad CA, Lang FF, Berven FS, Végvári A, Rezeli M, Marko-Varga G, Hober S, Nilsson CL.

J Proteome Res. 2014 Jan 3;13(1):191-9. doi: 10.1021/pr400786s. Epub 2013 Dec 3.

PMID:
24266786
33.

Antibodies biotinylated using a synthetic Z-domain from protein A provide stringent in situ protein detection.

Andersson S, Konrad A, Ashok N, Pontén F, Hober S, Asplund A.

J Histochem Cytochem. 2013 Nov;61(11):773-84. doi: 10.1369/0022155413502360. Epub 2013 Aug 6.

34.

Developments in biobanking workflow standardization providing sample integrity and stability.

Malm J, Fehniger TE, Danmyr P, Végvári A, Welinder C, Lindberg H, Appelqvist R, Sjödin K, Wieslander E, Laurell T, Hober S, Berven FS, Fenyö D, Wang X, Andrén PE, Edula G, Carlsohn E, Fuentes M, Nilsson CL, Dahlbäck M, Rezeli M, Erlinge D, Marko-Varga G.

J Proteomics. 2013 Dec 16;95:38-45. doi: 10.1016/j.jprot.2013.06.035. Epub 2013 Jul 13.

PMID:
23856607
35.

Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.

Nilvebrant J, Astrand M, Löfblom J, Hober S.

Cell Mol Life Sci. 2013 Oct;70(20):3973-85. doi: 10.1007/s00018-013-1370-9. Epub 2013 Jun 2.

PMID:
23728098
36.

Contribution of antibody-based protein profiling to the human Chromosome-centric Proteome Project (C-HPP).

Fagerberg L, Oksvold P, Skogs M, Algenäs C, Lundberg E, Pontén F, Sivertsson A, Odeberg J, Klevebring D, Kampf C, Asplund A, Sjöstedt E, Al-Khalili Szigyarto C, Edqvist PH, Olsson I, Rydberg U, Hudson P, Ottosson Takanen J, Berling H, Björling L, Tegel H, Rockberg J, Nilsson P, Navani S, Jirström K, Mulder J, Schwenk JM, Zwahlen M, Hober S, Forsberg M, von Feilitzen K, Uhlén M.

J Proteome Res. 2013 Jun 7;12(6):2439-48. doi: 10.1021/pr300924j. Epub 2012 Dec 31.

PMID:
23276153
37.

The albumin-binding domain as a scaffold for protein engineering.

Nilvebrant J, Hober S.

Comput Struct Biotechnol J. 2013 Sep 1;6:e201303009. doi: 10.5936/csbj.201303009. eCollection 2013. Review.

38.

Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium.

Nilsson CL, Berven F, Selheim F, Liu H, Moskal JR, Kroes RA, Sulman EP, Conrad CA, Lang FF, Andrén PE, Nilsson A, Carlsohn E, Lilja H, Malm J, Fenyö D, Subramaniyam D, Wang X, Gonzales-Gonzales M, Dasilva N, Diez P, Fuentes M, Végvári Á, Sjödin K, Welinder C, Laurell T, Fehniger TE, Lindberg H, Rezeli M, Edula G, Hober S, Marko-Varga G.

J Proteome Res. 2013 Jan 4;12(1):135-50. doi: 10.1021/pr3008607. Epub 2012 Dec 18.

39.

Miniaturized and automated high-throughput verification of proteins in the ISET platform with MALDI MS.

Adler B, Boström T, Ekström S, Hober S, Laurell T.

Anal Chem. 2012 Oct 16;84(20):8663-9. doi: 10.1021/ac3017983. Epub 2012 Sep 24.

PMID:
22971087
40.

Editorial: Biotech reviews on plants, lignocellulose, sequencing, genome engineering and Aspergilli.

Hober S.

Biotechnol J. 2012 Sep;7(9):1057. doi: 10.1002/biot.201200296.

PMID:
22961966
41.

Orthogonal protein purification facilitated by a small bispecific affinity tag.

Nilvebrant J, Alm T, Hober S.

J Vis Exp. 2012 Jan 16;(59). pii: 3370. doi: 10.3791/3370.

42.

Covalent immunoglobulin labeling through a photoactivable synthetic Z domain.

Konrad A, Karlström AE, Hober S.

Bioconjug Chem. 2011 Dec 21;22(12):2395-403. doi: 10.1021/bc200052h. Epub 2011 Nov 14.

PMID:
22026370
43.

Engineering bispecificity into a single albumin-binding domain.

Nilvebrant J, Alm T, Hober S, Löfblom J.

PLoS One. 2011;6(10):e25791. doi: 10.1371/journal.pone.0025791. Epub 2011 Oct 3.

44.

High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.

Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson LB, Påhlman S, Jirström K, Uhlen M.

Proteomics Clin Appl. 2011 Dec;5(11-12):624-35. doi: 10.1002/prca.201100020.

PMID:
21956899
45.

Editorial: biotech reviews - keeping up with current developments.

Hober S.

Biotechnol J. 2011 Sep;6(9):1031. doi: 10.1002/biot.201100414. No abstract available.

PMID:
21910253
46.

Translational database selection and multiplexed sequence capture for up front filtering of reliable breast cancer biomarker candidates.

Ståhl PL, Bjursell MK, Mahdessian H, Hober S, Jirström K, Lundeberg J.

PLoS One. 2011;6(6):e20794. doi: 10.1371/journal.pone.0020794. Epub 2011 Jun 15.

47.

Parallel production and verification of protein products using a novel high-throughput screening method.

Tegel H, Yderland L, Boström T, Eriksson C, Ukkonen K, Vasala A, Neubauer P, Ottosson J, Hober S.

Biotechnol J. 2011 Aug;6(8):1018-25. doi: 10.1002/biot.201000430. Epub 2011 Jun 16.

PMID:
21681961
48.

Novel antigen design for the generation of antibodies to G-protein-coupled receptors.

Larsson K, Hofström C, Lindskog C, Hansson M, Angelidou P, Hökfelt T, Uhlén M, Wernérus H, Gräslund T, Hober S.

J Immunol Methods. 2011 Jul 29;370(1-2):14-23. doi: 10.1016/j.jim.2011.05.001. Epub 2011 May 12.

PMID:
21605562
49.

Surrogate antigens as targets for proteome-wide binder selection.

Gustavsson E, Ek S, Steen J, Kristensson M, Älgenäs C, Uhlén M, Wingren C, Ottosson J, Hober S, Borrebaeck CA.

N Biotechnol. 2011 Jul;28(4):302-11. doi: 10.1016/j.nbt.2010.12.005. Epub 2011 Jan 11.

PMID:
21232647
50.

Enhancing the protein production levels in Escherichia coli with a strong promoter.

Tegel H, Ottosson J, Hober S.

FEBS J. 2011 Mar;278(5):729-39. doi: 10.1111/j.1742-4658.2010.07991.x. Epub 2011 Jan 12.

Supplemental Content

Support Center